# US 2010/0143270 A1 · Therapeutic cotinine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143270 A1
- Document ID: US20100143270A1
- Status: Published application
- Kind: A1
- Application number: 12/528,050
- Filed: 2008-02-21
- Published: 2010-06-10
- Earliest claimed: 2007-02-21
- Assignees: University of Louisville Research Foubdation
- Inventors: David Albert Scott; Michael Martin
- Web page: https://patentgrep.com/patent/US20100143270A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compositions for treating acute and/or chronic inflammation with cotinine or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method to treat acute inflammation comprising administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a mammal.

### Claim 2

A method to treat chronic inflammation, excluding inflammatory bowel disorders (IBD), comprising administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a mammal.

### Claim 3

A method of modulating activity of a cytokine comprising administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a mammal.

### Claim 4 (depends on 3)

The method of claim 3, wherein the activity of the cytokine is inhibited.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cytokine is IFN-γ IL-1β, IL-6, TNF-α, IL-12/IL-23.

### Claim 6 (depends on 3)

The method of claim 3, wherein the activity of the cytokine is stimulated.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cytokine is IL-10.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1 to 7, wherein the compound is formulated into a tablet or capsule, a transdermal delivery system, a chewing gum, a toothpaste, an interocular insert, an inhaler, or an aqueous solution.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1 to 8, wherein the compound is formulated as a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day.

### Claim 10 (depends on 1, 2)

The method of claims of claim 1 or 2, wherein the inflammation is associated with a peripheral disease.

### Claim 11 (depends on 1, 2)

The method of any of claim 1 or 2, wherein the inflammation is a pathogen-induced inflammation.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pathogen is a gram negative bacterium.

### Claim 13 (depends on 11)

The method of claim 11, wherein the pathogen is Porphyromonas gingivalis.

### Claim 14 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the inflammation is associated with anaphylactic shock, arthritis, asthma, cholecystitis, chronic obstructive pulmonary diseases, cystitis, dacryoadenitis, dermatomyositis, dermatitis, endocarditis, endometritis, fasciitis, fibrositis, gastritis, gingivitis, glossitis, mastitis, meningitis, myelitis, myocarditis, nephritis, neuritis, orchitis, osteisis, pancreatitis, parotitis, pericarditis, periodontitis, peritonitis, phlebitis, proctitis, prostatitis, pyelonephritis, rhinitis, sepsis and septic shock, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, vaginitis, vasculitis, vascular diseases, and/or vulvitis.

### Claim 15

The use of cotinine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for the treatment of acute inflammation in a mammal.

### Claim 16

The use of cotinine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for the treatment of chronic inflammation, excluding inflammatory bowel disorders (IBD), in a mammal.

### Claim 17

The use of cotinine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for the modulation of activity of a cytokine in a mammal.

### Claim 18

A pharmaceutical composition comprising cotinine, or a pharmaceutically acceptable salt thereof, in combination with any steroidal or non-steroidal anti-inflammatory drugs(s), and a pharmaceutically acceptable diluent or carrier.

### Claim 19

A method to suppress a pro-inflammatory response of monocytes
comprising administering a therapeutically effective amount of cotinine to a mammal.

### Claim 20

A method to prevent or treat acute bacterial and viral infections
comprising administering a therapeutically effective amount of cotinine to a mammal.

### Claim 21

A method preventing or treat a TLR-mediated inflammatory condition
comprising administering a therapeutically effective amount of cotinine to a mammal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the TLR-mediated inflammatory condition is arthritis, bronchitis, cancers, or vascular inflammation.

### Claim 23

An article of manufacture comprising, a packaging material and at least one unit dosage form of a pharmaceutical agent contained in the package wherein the pharmaceutical agent comprises cotinine or a pharmaceutically acceptable salt thereof in an amount effective to alleviate or reduce the symptoms of acute and/or chronic inflammation, and wherein the package includes instructions indicating use for alleviating acute and/or chronic inflammation.

### Claim 24 (depends on 23)

The article of manufacture of claim 23, wherein the instructions comprise a printed label, printed package insert, tag, cassette tape and the like.

### Claim 25 (depends on 23)

The article of manufacture of claim 23, wherein the packaging comprises a box, bottle, tube, spray or insufflator, intravenous bag, envelope or the like.

### Claim 26

Use of cotinine or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disease anaphylactic shock, arthritis, asthma, cholecystitis, chronic obstructive pulmonary diseases, cystitis, dacryoadenitis, dermatomyositis, dermatitis, endocarditis, endometritis, fasciitis, fibrositis, gastritis, gingivitis, glossitis, mastitis, meningitis, myelitis, myocarditis, nephritis, neuritis, orchitis, osteisis, pancreatitis, parotitis, pericarditis, periodontitis, peritonitis, phlebitis, proctitis, prostatitis, pyelonephritis, rhinitis, sepsis and septic shock, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, vaginitis, vasculitis, vascular diseases, and/or vulvitis.
